

Sevirumab

Cat. No.:	HY-P99900
CAS No.:	138660-96-5
Target:	CMV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC ₅₀ of 0.3 µg/mL ^{[1][2]} .
IC ₅₀ & Target	EC ₅₀ : 0.3 µg/mL (CMV) ^[1]
In Vitro	Sevirumab (MSL-109) perturbs the gH/gL homodimer rather than abolishing dimerization. Sevirumab may be splaying the dimer apart at sufficient distance to reduce fluorescence resonance energy transfer (FRET) and ultimately prevent proper gH/gL function ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Nokta M, et al. Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication. *Antiviral Res.* 1994 May;24(1):17-26.

[2]. Fouts AE, et al. Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109. *Proc Natl Acad Sci U S A.* 2014 Jun 3;111(22):8209-14.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA